UDFF and Auto pSWE accurately assess liver steatosis and fibrosis risk in obese patients with MASLD
Nina Dominik(Medical University of Vienna), David Bauer(Austrian Academy of Sciences), Gerhard Prager(Medical University of Vienna), Felix B. Langer, Daniel Moritz Felsenreich(Medical University of Vienna), Benedikt Simbrunner(Austrian Academy of Sciences), Behrang Mozayani(Medical University of Vienna), Lukas Hartl(Medical University of Vienna), Julia Jedamzik(Medical University of Vienna), Lisa Gensthaler(Medical University of Vienna), Laurenz Hauptmann(Medical University of Vienna), Larissa Nixdorf(Medical University of Vienna), Georg Semmler(University of Southern Denmark), Mattias Mandorfer(Medical University of Vienna), Thomas Reiberger(ERN GUARD-Heart), Benedikt Hofer(Austrian Academy of Sciences), Mathias Jachs(Medical University of Vienna), Michael Trauner(Medical University of Vienna), Lorenz Balcar(Medical University of Vienna), L. Fritz(Medical University of Vienna), Michael Schwarz(Medical University of Vienna)
Cited by 4
Related Papers
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
|Annual Review of Pathology Mechanisms of Disease|2018|561
Pathophysiological mechanisms of liver injury in COVID‐19
|Liver International|2020|399